OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth

Core Viewpoint - OSE Immunotherapeutics has appointed Marc Le Bozec as the permanent Chief Executive Officer, transitioning from his interim role, effective immediately [1][2]. Group 1: Leadership Transition - The Board of Directors unanimously confirmed Marc Le Bozec's transition from interim to permanent CEO after a thorough review of candidates [2]. - Dr. Markus Cappel, Chairman of the Board, expressed confidence in Le Bozec's leadership, highlighting his strategic vision and ability to unite the team [3]. Group 2: Company Vision and Goals - Marc Le Bozec emphasized the importance of accelerating breakthrough therapies and ensuring that novel medicines reach patients quickly [4]. - The company is committed to delivering life-changing treatments for patients with high unmet medical needs, focusing on immuno-oncology and immuno-inflammation [5]. Group 3: Compensation and Governance - The compensation policy for Marc Le Bozec will be published in the Company's 2025 Universal Registration Document and will be subject to approval at the Annual Shareholders' Meeting [6]. Group 4: Company Overview - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation, partnering with academic institutions and biopharmaceutical companies [7].